Last updated: March 5, 2024
Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Vascular Diseases
Dizzy/fainting Spells
Circulation Disorders
Treatment
Norepinephrine
Vasopressin
Phenylephrine
Clinical Study ID
NCT04053478
19-04
Ages 19-40 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who give written consent to participate in this study
- Patients with gestational age 37-41 weeks
- Patients of 19-40 years
- Non-laboring patients, not exposed to exogenous oxytocin
- Patients requiring elective primary or first repeat caesarean delivery
- Patients undergoing caesarean delivery under spinal anesthesia
Exclusion
Exclusion Criteria:
- Patients who refuse to give written informed consent
- Patients who require general anesthesia
- Patients in labor and those receiving oxytocin for induction of labor
- Emergency caesarean delivery in labor
- Patients who have had previous uterine surgery or >1 previous caesarean delivery
- Patients with any condition predisposing to uterine atony
- Patients on medications that could affect myometrial contractility, such as insulin,nifedipine, labetolol or magnesium sulfate.
Study Design
Total Participants: 144
Treatment Group(s): 4
Primary Treatment: Norepinephrine
Phase:
Study Start date:
July 08, 2019
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Mount Sinai Hospital
Toronto, Ontario M5G1X5
CanadaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.